On Thursday, Raptor Pharmaceutical Corp. (NASDAQ:RPTP)’s shares declined -8.03% to $12.02.
Raptor Pharmaceutical Corp. (RPTP) declared financial results for the three and six months ended June 30, 2015 and offered an update on recent corporate developments.
Summary
Global net product sales for PROCYSBI(R) (cysteamine bitartrate) delayed-release capsules were $23.3 million for the second quarter ended June 30, 2015 contrast to $16.3 million for the same period in 2014, representing a growth of 43% year over year.
Raptor stated a net loss on a GAAP basis of $13.9 million for the second quarter, or $0.17 per share.
Cash and cash equivalents were $193.0 million while short-term investments were $27.5 million as of June 30, 2015. Cash balances were bolstered by $92.0 million in net proceeds from an underwritten public offering accomplished in April.
Raptor Pharmaceutical Corp., a biopharmaceutical company, focuses on developing and commercializing life-altering therapeutics that treat debilitating and often fatal diseases. The company offers PROCYSBI, a delayed-release capsule, which is used for the administration of nephropathic cystinosis in adults, in addition to in six years and older children in the United States, in the 28 member states of the European Union, Norway, Liechtenstein, and Iceland. Its clinical development programs comprise RP103 that is used as a treatment for Huntington’s disease; RP103 as a treatment for non-alcoholic fatty liver disease in children; and RP103 as a treatment for mitochondrial disorders, counting Leigh syndrome.
Medivation Inc (NASDAQ:MDVN)’s shares dropped -5.93% to $92.25.
Medivation, Inc. ( MDVN) stated its financial results for the second quarter ended June 30, 2015. U.S. net sales of XTANDI® (enzalutamide) capsules, as stated by Astellas Pharma Inc., were $298.4 million for the quarter (+108% vs. preceding year). Second quarter U.S. net sales raised by 33% contrast with first quarter 2015 net sales of $224.0 million. We estimate second quarter 2015 unit demand raised by a low- to mid-teens percentage rate, contrast with unit demand in the first quarter 2015. In addition, based on information offered by Astellas, a lower gross-to-net discount rate was applied to second quarter gross sales (contrast with the first quarter rate), and a $2.8 million favorable adjustment was recorded in the second quarter by Astellas with respect to gross-to-net discount related to previous period gross sales.
Medivation, Inc., a biopharmaceutical company, focuses on the development and commercialization of novel therapies to treat serious diseases in the United States. It offers XTANDI for the treatment of post-chemotherapy metastatic castration-resistant prostate cancer (mCRPC) patients.
At the end of Thursday’s trade, Guess?, Inc. (NYSE:GES)‘s shares dipped -2.83% to $20.58.
Paul Marciano, Co-Founder and Chief Executive Officer of Guess?, Inc. (GES), announced today that Victor Herrero will be his successor and new CEO of Guess?, Inc. in August 2015. Paul Marciano will replace Maurice Marciano as Executive Chairman of the Board and will continue serving as Chief Creative Officer. Maurice Marciano will remain a director, and has been named Chairman Emeritus by the Board of Directors.
Victor Herrero joins Guess? with over twenty years of global experience spanning Europe and Asia. Victor served as the head of Asia Pacific for Inditex Group, the world’s largest fashion retailer with brands including Zara, Massimo Dutti, Pull & Bear, Bershka, and Stradivarius. In the past 10 years, Victor was responsible for building Inditex’s multi-billion dollar business in Asia.
Guess?, Inc. designs, markets, distributes, and licenses lifestyle collections of contemporary apparel and accessories for men, women, and children that reflect the American lifestyle and European fashion sensibilities. It operates through North American Retail, Europe, Asia, North American Wholesale, and Licensing segments. The company’s clothing collection comprises jeans, pants, skirts, dresses, shorts, blouses, shirts, jackets, knitwear, and intimate apparel. It also grants licenses to manufacture and distribute various products that complement its apparel lines, such as eyewear, watches, handbags, footwear, kids and infants apparel, outerwear, swimwear, fragrance, jewelry, and other fashion accessories.
PVH Corp (NYSE:PVH), ended its Thursday’s trading session with -2.04% loss, and closed at $114.98.
SPEEDO USA, a division of PVH Corp. (PVH), declared that it will release its second quarter 2015 earnings results on Wednesday, August 26, 2015 after the market closes. PVH will sponsor a conference call on Thursday, August 27, 2015 at 9:00 A.M. Eastern Time, hosted by Emanuel Chirico, Chairman and Chief Executive Officer, and Michael Shaffer, Executive Vice President and Chief Operating & Financial Officer, to talk about the results.
PVH Corp. operates as an apparel company in the United States and internationally. It designs, markets, and retails men’s and women’s apparel and accessories, branded dress shirts, neckwear, sportswear, jeanswear, intimate apparel, swim products, handbags, footwear, golf apparel, fragrances, cosmetics, eyewear, hosiery, socks, jewelry, watches, outerwear, small leather goods, and home furnishings, in addition to other related products.
DISCLAIMER:
This article is published by www.wsnewspublishers.com. The Content included in this article is just for informational purposes only. All information used in this article is believed to be from reliable sources, but we make no representations or warranties of any kind, express or implied, about the completeness, accuracy, or reliability with respect to this article.
All visitors are advised to conduct their own independent research into individual stocks before making a purchase decision.
Information contained in this article contains forward-looking information within the meaning of Section 27A of the Securities Act of 1933 and Section 21E of the Securities Exchange Act of 1934, counting statements regarding the predictable continual growth of the market for the corporation’s products, the corporation’s ability to fund its capital requirement in the near term and in the long term; pricing pressures; etc.
Any statements that express or involve discussions with respect to predictions, expectations, beliefs, plans, projections, objectives, aims, assumptions, or future events or performance may be forward looking statements. Forward-looking statements are based on expectations, estimates, and projections at the time the statements are made that involve a number of risks and uncertainties which could cause actual results or events to differ materially from those presently anticipated. Forward looking statements may be identified through the use of such words as expects, will, anticipates, estimates, believes, or by statements indicating certain actions may, could, should might occur.
